Live Price Coverage: Dicerna Pharmaceuticals Inc Has Another Very Strong Trading Session

Live Price Coverage: Dicerna Pharmaceuticals Inc Has Another Very Strong Trading Session

The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is a huge mover today! About 1.33M shares traded hands or 407.72% up from the average. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has 0.00% since February 26, 2016 and is . It has underperformed by 10.42% the S&P500.
The move comes after 5 months positive chart setup for the $134.10M company. It was reported on Sep, 30 by Barchart.com. We have $16.26 PT which if reached, will make NASDAQ:DRNA worth $236.02 million more.

Analysts await Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to report earnings on November, 8. They expect $-0.86 earnings per share, down 4.88% or $0.04 from last year’s $-0.82 per share. After $-0.75 actual earnings per share reported by Dicerna Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 14.67% negative EPS growth.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Ratings Coverage

Out of 4 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Dicerna Pharmaceuticals has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock has “Neutral” rating given by Chardan Capital Markets on Monday, August 15. The rating was maintained by Stifel Nicolaus on Tuesday, May 10 with “Buy”. On Monday, August 10 the stock rating was maintained by Stifel Nicolaus with “Buy”. Stifel Nicolaus maintained Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) on Thursday, June 30 with “Buy” rating. The stock has “Outperform” rating given by Cowen & Co on Tuesday, September 8. The company was maintained on Thursday, June 30 by Chardan Capital Markets. The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) earned “Buy” rating by Stifel Nicolaus on Wednesday, November 11.

According to Zacks Investment Research, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 0.76 in 2016 Q2. Its down 0.24, from 1 in 2016Q1. The ratio dropped, as 15 funds sold all Dicerna Pharmaceuticals Inc shares owned while 18 reduced positions. 11 funds bought stakes while 14 increased positions. They now own 12.70 million shares or 13.90% less from 14.75 million shares in 2016Q1.
Blackrock Institutional Trust Na last reported 0% of its portfolio in the stock. Renaissance Lc accumulated 75,600 shares or 0% of the stock. Blackrock holds 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 3,874 shares. Moreover, Credit Suisse Ag has 0% invested in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 54,112 shares. Bancorp Of New York Mellon Corp has invested 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Lmr Llp owns 11,757 shares or 0.01% of their US portfolio. Manufacturers Life Insurance The, a Ontario – Canada-based fund reported 671 shares. Oxford Asset Mgmt reported 286,413 shares or 0.04% of all its holdings. Abingworth Llp holds 2.96% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 945,757 shares. Jacobs Levy Equity Management Inc last reported 0.01% of its portfolio in the stock. Alpine Prtnrs Vi Limited Liability Corporation has 20,488 shares for 0.03% of their US portfolio. State Bank Of America De last reported 7,326 shares in the company. Ra Cap Mngmt Ltd Liability has 1.01% invested in the company for 2.43M shares. Palo Alto accumulated 0.06% or 267,890 shares. Dafna Cap Ltd Liability Corporation, a California-based fund reported 119,300 shares.

Insider Transactions: Since May 12, 2016, the stock had 1 buy, and 0 sales for $16,434 net activity. Weissman James B bought $16,434 worth of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) on Thursday, May 12.

More important recent Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) news were published by: Finance.Yahoo.com which released: “Dicerna Pharmaceuticals (DRNA) Worth a Look: Stock Up 6%” on September 22, 2016, also Businesswire.com published article titled: “Dicerna Prioritizes Resources to Advance GalXCâ„¢ Product Candidates”, Fool.com published: “Why Dicerna Pharmaceuticals Inc Stock Skyrocketed” on June 30, 2014. More interesting news about Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) was released by: Businesswire.com and their article: “Dicerna Pharmaceuticals Appoints John “Jack” Green Interim Chief Financial Officer” with publication date: December 15, 2015.

DRNA Company Profile

Dicerna Pharmaceuticals, Inc., incorporated on October 24, 2006, is a ribonucleic acid (RNA) interference biopharmaceutical company. The Firm operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Firm is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Firm uses its RNAi technology platform to build a pipeline in these therapeutic areas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment